Eli Lilly's retatrutide shows promising weight loss results in clinical trials
Here's what it means for you.
Eli Lilly's retatrutide could revolutionize obesity treatment with its impressive weight loss results.
What happened
Eli Lilly announced promising results from trials of its new weight loss drug, retatrutide.
The Context
- Participants lost up to 30% of their body weight, equating to about 85 pounds.
- The drug aims to expand Eli Lilly's obesity treatment portfolio amid increasing demand.
- It may be more effective than currently available GLP-1 medications.
Takeaway
The promising results of retatrutide could lead to its FDA approval and a significant shift in obesity treatment options.
Top international stories selected by The Guardian editors.
"The Guardian is known for its progressive editorial stance and in-depth analysis."
— A47 Editor
New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly has announced that its new weight-loss drug, retatrutide, has shown significant efficacy in a large clinical trial, with participants losing an average of 28% of their body weight over 80 weeks. This performance surpasses existing obesity m...
Reports on science policy, discoveries, and public debate in the scientific realm.
"The Guardian’s science section is known for thoughtful and critical reporting on global research, ethics, and public understanding of science."
— A47 Editor
New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly has announced that its new weight-loss drug, retatrutide, has demonstrated significant efficacy in a recent trial, with participants losing an average of 28% of their body weight over 80 weeks. This positions retatrutide as a potentially su...
Public health news, medical research, and wellness coverage.
"NBC News is a mainstream outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
New Weight Loss Drug Retatrutide Delivers Stunning Results
Eli Lilly's latest weight loss drug, retatrutide, has demonstrated remarkable efficacy in clinical trials, showing an average weight loss of 28% among participants over 80 weeks. This positions retatrutide as a potentially more effective alternative ...
National headlines across the United States including breaking stories and societal issues.
"NBC News is a mainstream media outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
New Weight Loss Drug Retatrutide Delivers Stunning Results
Eli Lilly's new weight loss drug, retatrutide, has shown remarkable efficacy in clinical trials, outperforming existing GLP-1 medications. The drug mimics three hormones that regulate hunger and fat burning, leading to significant weight loss among p...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Eli Lilly’s New Weight-Loss Treatment Shows Promising Results
Eli Lilly has announced promising results from a clinical trial of its investigational weight-loss drug, which demonstrated clinically meaningful weight loss. This development comes as the company seeks to expand its obesity treatment portfolio in re...
Scientific research, space, environment, and health coverage.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
Experimental Drug Yields Dramatic Weight Loss
Eli Lilly announced that its experimental drug, retatrutide, has led to an average weight loss of 28 percent among participants after 80 weeks, marking a significant breakthrough in obesity treatment. This development highlights the potential of reta...
Markets, economy, and company analysis from NYT’s business desk.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
Experimental Drug Yields Dramatic Weight Loss
Eli Lilly announced that its experimental drug, retatrutide, has led to an average weight loss of 28 percent among participants after 80 weeks, marking a significant breakthrough in obesity treatment. This development highlights the potential of reta...
Health trends, medical research, and fitness reporting.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
Experimental Drug Yields Dramatic Weight Loss
Eli Lilly announced that its experimental drug, retatrutide, has led to an average weight loss of 28 percent among participants after 80 weeks, marking a significant breakthrough in obesity treatment. This development highlights the potential of reta...
Public health news, medical research, and wellness coverage.
"NBC News is a mainstream outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
Eli Lilly announced that its experimental weight loss drug, retatrutide, has shown promising results in a late-stage clinical trial, with participants losing up to 30% of their body weight, approximately 85 pounds. This significant weight loss highli...
National headlines across the United States including breaking stories and societal issues.
"NBC News is a mainstream media outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
Eli Lilly announced that its experimental weight loss drug, retatrutide, has shown promising results in a late-stage clinical trial, with participants losing up to 30% of their body weight, approximately 85 pounds. This significant weight loss highli...